An interventional study of ABLE Exoskeleton in Acquired Brain Injury (Including Stroke), sponsored by ABLE Human Motion S.L.. Completed at 3 sites in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Brain Injuries with a site in Spain — 11 open to participants now, 13 under way, none of them phase 3. Brain Injuries · Spain.
Among the 43 studies in Brain Injuries with a site in Spain, this one is the 27th largest by enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2025, is one of 27 with no phase, and was the 37th registered.
947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.
Browse Brain Injuries studies →11 of the 43 studies in Brain Injuries with a site in Spain are open now. Recruiting first, the newest first:
Hospitales Nisa · Sites in Spain
Ages 18–85
Inrobics Social Robotics, S.L. · Sites in Spain
Ages 7–16
University of Salamanca · Sites in Spain
Ages 18+
Universidade da Coruña · Sites in Spain
Ages 7–18
Institut Guttmann · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 41 across 613 interventional studies indexed under Brain Injuries.
Median enrollment 30 across the 30 interventional studies, 100 across the 13 observational. Of the 27 that completed or were terminated, 3 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 43 have an industry lead sponsor. The 10 most frequent:
ABLE Human Motion S.L. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
ABLE Human Motion S.L. has 3 studies filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
5 of the studies in Brain Injuries with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT07448103Inrobics Social Robotics, S.L.Hospital and Home Rehabilitation Based on Social Care Robotics and Artificial Intelligence for Pediatric Patients | 2027-02 |
| NCT06804486Universidade da CoruñaExercise and Physical Activity in Children With Pediatric Acquired Brain Injury | 2027-06-28 |
| NCT06895226Universidade da CoruñaExercise and Physical Activity in Adults With Acquired Brain Injury | 2027-08-01 |
| NCT07817316Hospitales NisaEffects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Brain Injuries with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to validate the safety and clinical performance of the ABLE Exoskeleton device in people with acquired brain injury during a 10-session gait training program in a clinical setting.
The secondary objective of the study focuses on obtaining preliminary data on the potential clinical and psychosocial benefits of the product.
This is a pre-post, multicenter, quasi-experimental study with an estimated duration of 17 weeks. The study will be conducted at the Centro Europeo de Neurociencias (CEN), Cefine Neurología (CEFINE), and Fundación Step by Step Foundation, where a minimum of 15 participants (5 per center) are expected to be recruited within a period of 8 weeks.
After obtaining informed consent, through the Patient Information Sheet and the Informed Consent Form, the selection of the participants will be carried out to determine their inclusion in the study. Subjects who do not meet all the inclusion and exclusion criteria during the screening visit will be excluded from the study. At the latest, one week after the screening visit, the participants will undergo a baseline assessment without the medical device.
Participants will undergo a 10-session training program with the ABLE Exoskeleton device for a maximum duration of 6 weeks. Sessions will be conducted 2 times per week. Each session will last approximately 60 minutes. During the training period, session data will be taken to assess the safety and clinical performance of the device. At the latest, one week after the last training session, a post-training assessment will be performed. Finally, two weeks after the last training session, a follow-up assessment will be made to the participants via a telephone call to review any adverse events (AE) reported between the end of the training and the follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.
Device: ABLE Exoskeleton
Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.
Number and type of device-related Adverse Events
To assess safety, the number of Severe Adverse Events (SAE), Adverse Events (AE) and drop-outs due to the device will be assessed and reported.
Time frame: From baseline to follow-up (up to 2 weeks after end of intervention)
Level of Assistance (LoA) to don/doff the device
Level of Assistance (LoA) to don/doff the device will be measured in every session. The level of assistance will be measured using a 6-item scale, from Total assistance to Independence, with Independence being the best outcome possible. Different assistance levels are defined taking into account the degree of participation of both the participant and the therapist on performing the activity.
Time frame: Up to 6 weeks
Time taken to don/doff the device
The time taken to don/doff the device will be measured in every session. Time will be measured in minutes and seconds for each activity. Donning time will start from the moment the participant is ready to transfer into the device until all the straps and clips are correctly tightened. Doffing time will start from the moment the participant starts taking off the device until they have completely removed it.
Time frame: Up to 6 weeks
Number of steps walked
In each gait training session, the number of steps taken (step count) with the device will be automatically measured and registered by the device
Time frame: Up to 6 weeks
Distance walked
In each gait training session, the distance walked (in meters) with the device will be automatically measured and registered by the device
Time frame: Up to 6 weeks
Time spent upright and time spent walking
In each gait training session, the time spent upright (in minutes) and the time spent walking (in minutes) with the device will be automatically measured and registered by the device
Time frame: Up to 6 weeks
Number of therapists assisting the session
In each gait training session, the number of therapists assisting will be recorded
Time frame: Up to 6 weeks
Level of Assistance (LoA) during training
Four therapy activity tasks will be attempted every session by the participant. The therapist will record the level of assistance required to complete each task during the session, using a 6-item scale, from Total assistance to Independence, with Independence being the best outcome possible. The tasks are the following: sit-to-stand, walk 10 meters, turn 180 degrees, and stand-to-sit.
Time frame: Up to 6 weeks
Lower extremity muscle strenght
The Daniels Muscle Testing scale will be used to measure the strength of muscles in the lower extremities. Scores range from 0 (absence of muscle activity) to 5 (normal muscle activity)
Time frame: At baseline (day 0) and post-training (up to 7 weeks)
Functional Ambulation Category (FAC)
The patient's walking ability is evaluated with the Functional Ambulation Category (FAC) scale. It has 6 categories, from 0 (patient who is not able to walk) to 5 (independent patient who does not need any help to walk)
Time frame: At baseline(day 0) and post-training (up to 7 weeks)
10-Meter Walking Test (10MWT)
The 10-Meter Walking Test (10MWT) test measures the time a person needs to walk 10 meters. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.
Time frame: At baseline(day 0) and post-training (up to 7 weeks)
6-Minute Walk Test (6MWT)
The 6-Minute Walk Test (6MWT) measures the distance a person can walk in 6 minutes. This test will be assessed at baseline and at the end of the gait training program without the device to assess the change in the walking function after the training
Time frame: At baseline (day 0) and post-training (up to 7 weeks)
Timed Up and Go (TUG)
The Timed Up-and-Go Test (TUG) measures the time it takes a person to get up from a chair, walk 3 meters, turn around, and sit down again. This test will be performed in the pre-post evaluations without the device to assess the change in the walking function after the training.
Time frame: At baseline (day 0) and post-training (up to 7 weeks)
Trunk Impairment Scale (TIS)
The Trunk Impairment Scale (TIS) measures the motor impairment of the trunk through the evaluation of static and dynamic sitting balance as well as coordination of trunk movement. The total score ranges from 0 (minimal performance) to 23 (perfect performance).
Time frame: At baseline (day 0) and post-training (up to 7 weeks)
Berg Balance Scale (BBS)
The Berg Balance Scale (BBS) is used to assess the patient's ability to safely stabilize while performing certain tasks. It consists of a list of 14 items. Each item is evaluated through an ordinal scale ranging from 0 (lowest level of functionality) to 4 (highest level of functionality).
Time frame: At baseline and post-training (up to 7 weeks)
Modified Ashworth Scale (MAS)
The Modified Ashworth Scale (MAS) measures spasticity in patients with lesions to the central nervous system. The scale assigns a grade of spasticity from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension).
Time frame: At selection, baseline and post-training (up to 7 weeks)
Location and level of pain
The location and level of pain using the numeric rating scale (NRS) will be assessed. Each value is scored on a 0 to 10 scale, where 0 represents no pain and 10 represents the worst pain imaginable.
Time frame: From baseline to post-training (up to 7 weeks)
Borg Rating of Perceived Exertion
The Borg Rating of Perceived Exertion (RPE) scale is used to measure a person's perception of their effort and exertion, breathlessness, and fatigue during physical activity. Scores range from 6 (no exertion at all) to 20 (maximal exertion).
Time frame: From baseline to post-training (up to 7 weeks)
Functional Independence Measure (FIM)
The Functional Independence Scale (FIM) is a widely used instrument to assess the patient's outcomes and progress in rehabilitation programs. It is an indicator of disability, which measures how much assistance the patient needs to perform activities of daily living . It includes 18 activities that are measured on a 7-level scale, with 1 being indicative of total assistance and 7 of complete independence.
Time frame: At baseline and post-training (up to 7 weeks)
Level of motivation
Participants' perceptions on the level of motivation generated by the program with the ABLE Exoskeleton will be evaluated by the completion of a self-report questionnaire using a 7-point Likert scale. This questionnaire has been designed by the researchers.
Time frame: At post-training (up to 7 weeks from baseline)
Self-perceived impact on general health status
Participants' perceptions of the impact on their general health will be evaluated by the completion of a self-report questionnaire on the perceived impact on general health. This questionnaire has been designed by the researchers and intends to identify to what extent participants feel that the ABLE Exoskeleton contributed to a change in their health. The questionnaire covers 7 categories (cardiovascular system, musculoskeletal pain, neuropathic pain, bladder and bowel, spasticity, and sleep quality) using a 7-point Likert scale to assess the change.
Time frame: At post-training (up to 7 weeks)
Psychosocial Impact of Assistive Devices Scale (PIADS) score
The Psychosocial Impact of Assistive Devices Scale (PIADS) is a 26-item, self-reported questionnaire that provides a measure of user perception and other psychological factors associated with assistive technology devices. Scores range from -78 (maximum negative impact) to +78 (maximum positive impact). It will be used to assess the effects of the ABLE Exoskeleton on functional independence, well-being, and quality of life of participants after the training program experience
Time frame: At post-training (up to 7 weeks)
Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score
The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) is a 12-item outcome measure that assesses user satisfaction with two components (Device and Services) using a 5-point scale ranging from 1 (not satisfied) to 5 (very satisfied). Only the 8 items referred to the device will be evaluated from participants and the whole 12 items from the therapists to measure user satisfaction with the ABLE Exoskeleton after the training program experience
Time frame: At post-training (up to 7 weeks)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Dec 2025, 5 months.
Of 298 interventional studies with no phase under Brain Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ABLE Human Motion S.L.